| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| VRTX - Vertex Pharmaceuticals Inc | BUY | 780 @ USD 460.59 | USD 359,260 | The ETF bought 780 new shares of VRTX (Vertex Pharmaceuticals Inc). The shares were bought for an average price of 460.59 compared to the previous average buy price of 427.901. This is 7.6% higher than average price of previous purchases of VRTX. |
| GILD - Guild Esports Plc | BUY | 2,688 @ USD 122.6 | USD 329,549 | The ETF bought 2688 new shares of GILD (Guild Esports Plc). The shares were bought for an average price of 122.6 compared to the previous average buy price of 117.298. This is 4.5% higher than average price of previous purchases of GILD. |
| AMGN - Amgen Inc | BUY | 980 @ USD 325.54 | USD 319,029 | The ETF bought 980 new shares of AMGN (Amgen Inc). The shares were bought for an average price of 325.54 compared to the previous average buy price of 300.881. This is 8.2% higher than average price of previous purchases of AMGN. |
| REGN - Regeneron Pharmaceuticals Inc | BUY | 322 @ USD 768 | USD 247,296 | The ETF bought 322 new shares of REGN (Regeneron Pharmaceuticals Inc). The shares were bought for an average price of 768 compared to the previous average buy price of 652.256. This is 17.7% higher than average price of previous purchases of REGN. |
| AZN - AstraZeneca PLC | BUY | 1,816 @ USD 93.63 | USD 170,032 | The ETF bought 1816 new shares of AZN (AstraZeneca PLC). The shares were bought for an average price of 93.63 compared to the previous average buy price of 80.1042. This is 16.9% higher than average price of previous purchases of AZN. |
| ALNY - Alnylam Pharmaceuticals Inc | BUY | 412 @ USD 370.91 | USD 152,815 | The ETF bought 412 new shares of ALNY (Alnylam Pharmaceuticals Inc). The shares were bought for an average price of 370.91 compared to the previous average buy price of 395.683. This is -6.3% lower than average price of previous purchases of ALNY. |
| INSM - Insmed Inc | BUY | 664 @ USD 167.72 | USD 111,366 | The ETF bought 664 new shares of INSM (Insmed Inc). The shares were bought for an average price of 167.72 compared to the previous average buy price of 142.513. This is 17.7% higher than average price of previous purchases of INSM. |
| BIIB - Biogen Inc | BUY | 456 @ USD 185.63 | USD 84,647 | The ETF bought 456 new shares of BIIB (Biogen Inc). The shares were bought for an average price of 185.63 compared to the previous average buy price of 150.058. This is 23.7% higher than average price of previous purchases of BIIB. |
| ARGX - argenx NV ADR | BUY | 90 @ USD 796 | USD 71,640 | The ETF bought 90 new shares of ARGX (argenx NV ADR). The shares were bought for an average price of 796 compared to the previous average buy price of 718.567. This is 10.8% higher than average price of previous purchases of ARGX. |
| RVMD - Revolution Medicines Inc | BUY | 602 @ USD 117.17 | USD 70,536 | The ETF bought 602 new shares of RVMD (Revolution Medicines Inc). The shares were bought for an average price of 117.17 compared to the previous average buy price of 51.5873. This is 127.1% higher than average price of previous purchases of RVMD. |
| ILMN - Illumina Inc | BUY | 476 @ USD 145.55 | USD 69,282 | The ETF bought 476 new shares of ILMN (Illumina Inc). The shares were bought for an average price of 145.55 compared to the previous average buy price of 106.803. This is 36.3% higher than average price of previous purchases of ILMN. |
| INCY - Incyte Corporation | BUY | 610 @ USD 106.33 | USD 64,861 | The ETF bought 610 new shares of INCY (Incyte Corporation). The shares were bought for an average price of 106.33 compared to the previous average buy price of 82.2964. This is 29.2% higher than average price of previous purchases of INCY. |
| UTHR - United Therapeutics Corporation | BUY | 134 @ USD 482.39 | USD 64,640 | The ETF bought 134 new shares of UTHR (United Therapeutics Corporation). The shares were bought for an average price of 482.39 compared to the previous average buy price of 383.396. This is 25.8% higher than average price of previous purchases of UTHR. |
| RPRX - Royalty Pharma Plc | BUY | 1,330 @ USD 40.26 | USD 53,546 | The ETF bought 1330 new shares of RPRX (Royalty Pharma Plc). The shares were bought for an average price of 40.26 compared to the previous average buy price of 36.8134. This is 9.4% higher than average price of previous purchases of RPRX. |
| MEDP - Medpace Holdings Inc | BUY | 88 @ USD 599.21 | USD 52,730 | The ETF bought 88 new shares of MEDP (Medpace Holdings Inc). The shares were bought for an average price of 599.21 compared to the previous average buy price of 449.565. This is 33.3% higher than average price of previous purchases of MEDP. |
| ROIV - Roivant Sciences Ltd | BUY | 2,164 @ USD 22.16 | USD 47,954 | The ETF bought 2164 new shares of ROIV (Roivant Sciences Ltd). The shares were bought for an average price of 22.16 compared to the previous average buy price of 15.4255. This is 43.7% higher than average price of previous purchases of ROIV. |
| BBIO - BridgeBio Pharma Inc | BUY | 600 @ USD 76.84 | USD 46,104 | The ETF bought 600 new shares of BBIO (BridgeBio Pharma Inc). The shares were bought for an average price of 76.84 compared to the previous average buy price of 52.8692. This is 45.3% higher than average price of previous purchases of BBIO. |
| VTRS - Viatris Inc | BUY | 3,584 @ USD 12.68 | USD 45,445 | The ETF bought 3584 new shares of VTRS (Viatris Inc). The shares were bought for an average price of 12.68 compared to the previous average buy price of 9.99794. This is 26.8% higher than average price of previous purchases of VTRS. |
| GH - Guardant Health Inc | BUY | 402 @ USD 107.57 | USD 43,243 | The ETF bought 402 new shares of GH (Guardant Health Inc). The shares were bought for an average price of 107.57 compared to the previous average buy price of 69.8148. This is 54.1% higher than average price of previous purchases of GH. |
| IONS - Ionis Pharmaceuticals Inc | BUY | 504 @ USD 81.66 | USD 41,157 | The ETF bought 504 new shares of IONS (Ionis Pharmaceuticals Inc). The shares were bought for an average price of 81.66 compared to the previous average buy price of 57.5584. This is 41.9% higher than average price of previous purchases of IONS. |
| MRNA - Moderna Inc | BUY | 1,216 @ USD 33.84 | USD 41,149 | The ETF bought 1216 new shares of MRNA (Moderna Inc). The shares were bought for an average price of 33.84 compared to the previous average buy price of 28.3166. This is 19.5% higher than average price of previous purchases of MRNA. |
| NBIX - Neurocrine Biosciences Inc | BUY | 310 @ USD 132.66 | USD 41,125 | The ETF bought 310 new shares of NBIX (Neurocrine Biosciences Inc). The shares were bought for an average price of 132.66 compared to the previous average buy price of 135.809. This is -2.3% lower than average price of previous purchases of NBIX. |
| ASND - Ascendis Pharma AS | BUY | 192 @ USD 208.76 | USD 40,082 | The ETF bought 192 new shares of ASND (Ascendis Pharma AS). The shares were bought for an average price of 208.76 compared to the previous average buy price of 186.984. This is 11.6% higher than average price of previous purchases of ASND. |
| SMMT - Summit Therapeutics PLC | BUY | 2,316 @ USD 17.04 | USD 39,465 | The ETF bought 2316 new shares of SMMT (Summit Therapeutics PLC). The shares were bought for an average price of 17.04 compared to the previous average buy price of 20.4306. This is -16.6% lower than average price of previous purchases of SMMT. |
| SNY - Sanofi ADR | BUY | 824 @ USD 47.6 | USD 39,222 | The ETF bought 824 new shares of SNY (Sanofi ADR). The shares were bought for an average price of 47.6 compared to the previous average buy price of 49.8333. This is -4.5% lower than average price of previous purchases of SNY. |
| EXEL - Exelixis Inc | BUY | 834 @ USD 44.06 | USD 36,746 | The ETF bought 834 new shares of EXEL (Exelixis Inc). The shares were bought for an average price of 44.06 compared to the previous average buy price of 41.7671. This is 5.5% higher than average price of previous purchases of EXEL. |
| MDGL - Madrigal Pharmaceuticals Inc | BUY | 70 @ USD 510.53 | USD 35,737 | The ETF bought 70 new shares of MDGL (Madrigal Pharmaceuticals Inc). The shares were bought for an average price of 510.53 compared to the previous average buy price of 415.221. This is 23.0% higher than average price of previous purchases of MDGL. |
| BMRN - Biomarin Pharmaceutical Inc | BUY | 598 @ USD 57.71 | USD 34,511 | The ETF bought 598 new shares of BMRN (Biomarin Pharmaceutical Inc). The shares were bought for an average price of 57.71 compared to the previous average buy price of 57.1664. This is 1.0% higher than average price of previous purchases of BMRN. |
| RNA - Avidity Biosciences Inc | BUY | 468 @ USD 72.35 | USD 33,860 | The ETF bought 468 new shares of RNA (Avidity Biosciences Inc). The shares were bought for an average price of 72.35 compared to the previous average buy price of 51.17. This is 41.4% higher than average price of previous purchases of RNA. |
| CGON - CG Oncology, Inc. Common stock | BUY | 625 @ USD 53.72 | USD 33,575 | The ETF bought 625 new shares of CGON (CG Oncology, Inc. Common stock). The shares were bought for an average price of 53.72 compared to the previous average buy price of 33.1938. This is 61.8% higher than average price of previous purchases of CGON. |
| BNTX - BioNTech SE | BUY | 314 @ USD 102.18 | USD 32,085 | The ETF bought 314 new shares of BNTX (BioNTech SE). The shares were bought for an average price of 102.18 compared to the previous average buy price of 102.963. This is -0.8% lower than average price of previous purchases of BNTX. |
| JAZZ - Jazz Pharmaceuticals PLC | BUY | 190 @ USD 163.68 | USD 31,099 | The ETF bought 190 new shares of JAZZ (Jazz Pharmaceuticals PLC). The shares were bought for an average price of 163.68 compared to the previous average buy price of 136.281. This is 20.1% higher than average price of previous purchases of JAZZ. |
| ARWR - Arrowhead Pharmaceuticals Inc | BUY | 422 @ USD 65.93 | USD 27,822 | The ETF bought 422 new shares of ARWR (Arrowhead Pharmaceuticals Inc). The shares were bought for an average price of 65.93 compared to the previous average buy price of 31.1504. This is 111.7% higher than average price of previous purchases of ARWR. |
| AXSM - Axsome Therapeutics Inc | BUY | 156 @ USD 176.82 | USD 27,584 | The ETF bought 156 new shares of AXSM (Axsome Therapeutics Inc). The shares were bought for an average price of 176.82 compared to the previous average buy price of 124.851. This is 41.6% higher than average price of previous purchases of AXSM. |
| HALO - Halozyme Therapeutics Inc | BUY | 366 @ USD 72.42 | USD 26,506 | The ETF bought 366 new shares of HALO (Halozyme Therapeutics Inc). The shares were bought for an average price of 72.42 compared to the previous average buy price of 61.8137. This is 17.2% higher than average price of previous purchases of HALO. |
| CYTK - Cytokinetics Inc | BUY | 380 @ USD 64.64 | USD 24,563 | The ETF bought 380 new shares of CYTK (Cytokinetics Inc). The shares were bought for an average price of 64.64 compared to the previous average buy price of 49.364. This is 30.9% higher than average price of previous purchases of CYTK. |
| KRYS - Krystal Biotech Inc | BUY | 90 @ USD 272.13 | USD 24,492 | The ETF bought 90 new shares of KRYS (Krystal Biotech Inc). The shares were bought for an average price of 272.13 compared to the previous average buy price of 179.685. This is 51.4% higher than average price of previous purchases of KRYS. |
| NUVL - Nuvalent Inc | BUY | 224 @ USD 99.16 | USD 22,212 | The ETF bought 224 new shares of NUVL (Nuvalent Inc). The shares were bought for an average price of 99.16 compared to the previous average buy price of 89.1989. This is 11.2% higher than average price of previous purchases of NUVL. |
| RYTM - Rhythm Pharmaceuticals Inc | BUY | 208 @ USD 104.89 | USD 21,817 | The ETF bought 208 new shares of RYTM (Rhythm Pharmaceuticals Inc). The shares were bought for an average price of 104.89 compared to the previous average buy price of 84.3133. This is 24.4% higher than average price of previous purchases of RYTM. |
| PRAX - Praxis Precision Medicines Inc | BUY | 78 @ USD 275.74 | USD 21,508 | The ETF bought 78 new shares of PRAX (Praxis Precision Medicines Inc). The shares were bought for an average price of 275.74 compared to the previous average buy price of 129.64. This is 112.7% higher than average price of previous purchases of PRAX. |
| PTCT - PTC Therapeutics Inc | BUY | 250 @ USD 77.59 | USD 19,398 | The ETF bought 250 new shares of PTCT (PTC Therapeutics Inc). The shares were bought for an average price of 77.59 compared to the previous average buy price of 61.7203. This is 25.7% higher than average price of previous purchases of PTCT. |
| PCVX - Vaxcyte Inc | BUY | 408 @ USD 45.84 | USD 18,703 | The ETF bought 408 new shares of PCVX (Vaxcyte Inc). The shares were bought for an average price of 45.84 compared to the previous average buy price of 45.0353. This is 1.8% higher than average price of previous purchases of PCVX. |
| COGT - Cogent Biosciences Inc | BUY | 478 @ USD 34.76 | USD 16,615 | The ETF bought 478 new shares of COGT (Cogent Biosciences Inc). The shares were bought for an average price of 34.76 compared to the previous average buy price of 19.2209. This is 80.8% higher than average price of previous purchases of COGT. |
| CRNX - Crinetics Pharmaceuticals Inc | BUY | 296 @ USD 55.35 | USD 16,384 | The ETF bought 296 new shares of CRNX (Crinetics Pharmaceuticals Inc). The shares were bought for an average price of 55.35 compared to the previous average buy price of 38.311. This is 44.5% higher than average price of previous purchases of CRNX. |
| KYMR - Kymera Therapeutics Inc | BUY | 224 @ USD 73.09 | USD 16,372 | The ETF bought 224 new shares of KYMR (Kymera Therapeutics Inc). The shares were bought for an average price of 73.09 compared to the previous average buy price of 53.2091. This is 37.4% higher than average price of previous purchases of KYMR. |
| CRSP - Crispr Therapeutics AG | BUY | 296 @ USD 55.3 | USD 16,369 | The ETF bought 296 new shares of CRSP (Crispr Therapeutics AG). The shares were bought for an average price of 55.3 compared to the previous average buy price of 53.355. This is 3.6% higher than average price of previous purchases of CRSP. |
| PTGX - Protagonist Therapeutics Inc | BUY | 194 @ USD 80.25 | USD 15,569 | The ETF bought 194 new shares of PTGX (Protagonist Therapeutics Inc). The shares were bought for an average price of 80.25 compared to the previous average buy price of 65.3809. This is 22.7% higher than average price of previous purchases of PTGX. |
| ALKS - Alkermes Plc | BUY | 514 @ USD 29.62 | USD 15,225 | The ETF bought 514 new shares of ALKS (Alkermes Plc). The shares were bought for an average price of 29.62 compared to the previous average buy price of 30.0235. This is -1.3% lower than average price of previous purchases of ALKS. |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | BUY | 208 @ USD 69.36 | USD 14,427 | The ETF bought 208 new shares of GPCR (Structure Therapeutics Inc. American Depositary Shares). The shares were bought for an average price of 69.36 compared to the previous average buy price of 31.8401. This is 117.8% higher than average price of previous purchases of GPCR. |
| MIRM - Mirum Pharmaceuticals Inc | BUY | 160 @ USD 89.5 | USD 14,320 | The ETF bought 160 new shares of MIRM (Mirum Pharmaceuticals Inc). The shares were bought for an average price of 89.5 compared to the previous average buy price of 60.0555. This is 49.0% higher than average price of previous purchases of MIRM. |
| IMVT - Immunovant Inc | BUY | 546 @ USD 25.81 | USD 14,092 | The ETF bought 546 new shares of IMVT (Immunovant Inc). The shares were bought for an average price of 25.81 compared to the previous average buy price of 19.359. This is 33.3% higher than average price of previous purchases of IMVT. |
| ACAD - ACADIA Pharmaceuticals Inc | BUY | 526 @ USD 26.59 | USD 13,986 | The ETF bought 526 new shares of ACAD (ACADIA Pharmaceuticals Inc). The shares were bought for an average price of 26.59 compared to the previous average buy price of 22.2374. This is 19.6% higher than average price of previous purchases of ACAD. |
| SRRK - Scholar Rock Holding Corp | BUY | 320 @ USD 43.56 | USD 13,939 | The ETF bought 320 new shares of SRRK (Scholar Rock Holding Corp). The shares were bought for an average price of 43.56 compared to the previous average buy price of 37.0956. This is 17.4% higher than average price of previous purchases of SRRK. |
| FOLD - Amicus Therapeutics Inc | BUY | 960 @ USD 14.28 | USD 13,709 | The ETF bought 960 new shares of FOLD (Amicus Therapeutics Inc). The shares were bought for an average price of 14.28 compared to the previous average buy price of 8.26173. This is 72.8% higher than average price of previous purchases of FOLD. |
| ADMA - ADMA Biologics Inc | BUY | 742 @ USD 17.93 | USD 13,304 | The ETF bought 742 new shares of ADMA (ADMA Biologics Inc). The shares were bought for an average price of 17.93 compared to the previous average buy price of 17.843. This is 0.5% higher than average price of previous purchases of ADMA. |
| APGE - Apogee Therapeutics, Inc. Common Stock | BUY | 170 @ USD 77.65 | USD 13,201 | The ETF bought 170 new shares of APGE (Apogee Therapeutics, Inc. Common Stock). The shares were bought for an average price of 77.65 compared to the previous average buy price of 56.9187. This is 36.4% higher than average price of previous purchases of APGE. |
| LGND - Ligand Pharmaceuticals Incorporated | BUY | 62 @ USD 206.81 | USD 12,822 | The ETF bought 62 new shares of LGND (Ligand Pharmaceuticals Incorporated). The shares were bought for an average price of 206.81 compared to the previous average buy price of 150.622. This is 37.3% higher than average price of previous purchases of LGND. |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | BUY | 980 @ USD 12.98 | USD 12,720 | The ETF bought 980 new shares of AMRX (Amneal Pharmaceuticals, Inc. Class A Common Stock). The shares were bought for an average price of 12.98 compared to the previous average buy price of 9.74139. This is 33.2% higher than average price of previous purchases of AMRX. |
| GRAL - GRAIL, LLC | BUY | 120 @ USD 105.93 | USD 12,712 | The ETF bought 120 new shares of GRAL (GRAIL, LLC). The shares were bought for an average price of 105.93 compared to the previous average buy price of 64.9673. This is 63.1% higher than average price of previous purchases of GRAL. |
| ACLX - Arcellx Inc | BUY | 180 @ USD 64.87 | USD 11,677 | The ETF bought 180 new shares of ACLX (Arcellx Inc). The shares were bought for an average price of 64.87 compared to the previous average buy price of 71.9976. This is -9.9% lower than average price of previous purchases of ACLX. |
| VCYT - Veracyte Inc | BUY | 246 @ USD 43.45 | USD 10,689 | The ETF bought 246 new shares of VCYT (Veracyte Inc). The shares were bought for an average price of 43.45 compared to the previous average buy price of 35.1786. This is 23.5% higher than average price of previous purchases of VCYT. |
| ARQT - Arcutis Biotherapeutics Inc | BUY | 382 @ USD 26.78 | USD 10,230 | The ETF bought 382 new shares of ARQT (Arcutis Biotherapeutics Inc). The shares were bought for an average price of 26.78 compared to the previous average buy price of 20.4055. This is 31.2% higher than average price of previous purchases of ARQT. |
| IDYA - Ideaya Biosciences Inc | BUY | 272 @ USD 36.84 | USD 10,020 | The ETF bought 272 new shares of IDYA (Ideaya Biosciences Inc). The shares were bought for an average price of 36.84 compared to the previous average buy price of 26.5469. This is 38.8% higher than average price of previous purchases of IDYA. |
| TARS - Tarsus Pharmaceuticals Inc | BUY | 132 @ USD 75.53 | USD 9,970 | The ETF bought 132 new shares of TARS (Tarsus Pharmaceuticals Inc). The shares were bought for an average price of 75.53 compared to the previous average buy price of 57.2843. This is 31.9% higher than average price of previous purchases of TARS. |
| XENE - Xenon Pharmaceuticals Inc | BUY | 240 @ USD 41.23 | USD 9,895 | The ETF bought 240 new shares of XENE (Xenon Pharmaceuticals Inc). The shares were bought for an average price of 41.23 compared to the previous average buy price of 37.7305. This is 9.3% higher than average price of previous purchases of XENE. |
| TERN - Tern Plc | BUY | 280 @ USD 34.11 | USD 9,551 | The ETF bought 280 new shares of TERN (Tern Plc). The shares were bought for an average price of 34.11 compared to the previous average buy price of 12.2914. This is 177.5% higher than average price of previous purchases of TERN. |
| TVTX - Travere Therapeutics Inc | BUY | 278 @ USD 34.1 | USD 9,480 | The ETF bought 278 new shares of TVTX (Travere Therapeutics Inc). The shares were bought for an average price of 34.1 compared to the previous average buy price of 24.5103. This is 39.1% higher than average price of previous purchases of TVTX. |
| VERA - Vera Therapeutics Inc | BUY | 198 @ USD 46.46 | USD 9,199 | The ETF bought 198 new shares of VERA (Vera Therapeutics Inc). The shares were bought for an average price of 46.46 compared to the previous average buy price of 30.7497. This is 51.1% higher than average price of previous purchases of VERA. |
| IRON - Ironveld Plc | BUY | 116 @ USD 79.02 | USD 9,166 | The ETF bought 116 new shares of IRON (Ironveld Plc). The shares were bought for an average price of 79.02 compared to the previous average buy price of 66.55. This is 18.7% higher than average price of previous purchases of IRON. |
| SUPN - Supernus Pharmaceuticals Inc | BUY | 178 @ USD 51.36 | USD 9,142 | The ETF bought 178 new shares of SUPN (Supernus Pharmaceuticals Inc). The shares were bought for an average price of 51.36 compared to the previous average buy price of 39.7534. This is 29.2% higher than average price of previous purchases of SUPN. |
| APLS - Apellis Pharmaceuticals Inc | BUY | 394 @ USD 23.2 | USD 9,141 | The ETF bought 394 new shares of APLS (Apellis Pharmaceuticals Inc). The shares were bought for an average price of 23.2 compared to the previous average buy price of 21.264. This is 9.1% higher than average price of previous purchases of APLS. |
| ADPT - Adaptive Biotechnologies Corp | BUY | 476 @ USD 18.26 | USD 8,692 | The ETF bought 476 new shares of ADPT (Adaptive Biotechnologies Corp). The shares were bought for an average price of 18.26 compared to the previous average buy price of 13.5257. This is 35.0% higher than average price of previous purchases of ADPT. |
| DNLI - Denali Therapeutics Inc | BUY | 458 @ USD 17.95 | USD 8,221 | The ETF bought 458 new shares of DNLI (Denali Therapeutics Inc). The shares were bought for an average price of 17.95 compared to the previous average buy price of 16.1759. This is 11.0% higher than average price of previous purchases of DNLI. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | BUY | 246 @ USD 32.98 | USD 8,113 | The ETF bought 246 new shares of MLYS (Mineralys Therapeutics, Inc. Common Stock). The shares were bought for an average price of 32.98 compared to the previous average buy price of 26.3836. This is 25.0% higher than average price of previous purchases of MLYS. |
| EWTX - Edgewise Therapeutics Inc | BUY | 330 @ USD 24.13 | USD 7,963 | The ETF bought 330 new shares of EWTX (Edgewise Therapeutics Inc). The shares were bought for an average price of 24.13 compared to the previous average buy price of 18.1169. This is 33.2% higher than average price of previous purchases of EWTX. |
| IBRX - Immunitybio Inc | BUY | 3,074 @ USD 2.59 | USD 7,962 | The ETF bought 3074 new shares of IBRX (Immunitybio Inc). The shares were bought for an average price of 2.59 compared to the previous average buy price of 2.61953. This is -1.1% lower than average price of previous purchases of IBRX. |
| SYRE - Spyre Therapeutics Inc. | BUY | 242 @ USD 32.8 | USD 7,938 | The ETF bought 242 new shares of SYRE (Spyre Therapeutics Inc.). The shares were bought for an average price of 32.8 compared to the previous average buy price of 24.7116. This is 32.7% higher than average price of previous purchases of SYRE. |
| DYN - Dyne Therapeutics Inc | BUY | 446 @ USD 17.46 | USD 7,787 | The ETF bought 446 new shares of DYN (Dyne Therapeutics Inc). The shares were bought for an average price of 17.46 compared to the previous average buy price of 14.5491. This is 20.0% higher than average price of previous purchases of DYN. |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | BUY | 446 @ USD 17.46 | USD 7,787 | The ETF bought 446 new shares of DYN (DYNAGREEN EN.PR.GR.H YC 1). The shares were bought for an average price of 17.46 compared to the previous average buy price of 14.5491. This is 20.0% higher than average price of previous purchases of DYN. |
| RXRX - Recursion Pharmaceuticals Inc | BUY | 1,606 @ USD 4.81 | USD 7,725 | The ETF bought 1606 new shares of RXRX (Recursion Pharmaceuticals Inc). The shares were bought for an average price of 4.81 compared to the previous average buy price of 5.29971. This is -9.2% lower than average price of previous purchases of RXRX. |
| RARE - Ultragenyx | BUY | 300 @ USD 24.37 | USD 7,311 | The ETF bought 300 new shares of RARE (Ultragenyx). The shares were bought for an average price of 24.37 compared to the previous average buy price of 35.4952. This is -31.3% lower than average price of previous purchases of RARE. |
| RARE - WISETFWTMRARETFP | BUY | 300 @ USD 24.37 | USD 7,311 | The ETF bought 300 new shares of RARE (WISETFWTMRARETFP). The shares were bought for an average price of 24.37 compared to the previous average buy price of 35.4952. This is -31.3% lower than average price of previous purchases of RARE. |
| WVE - Wave Life Sciences Ltd | BUY | 522 @ USD 13.91 | USD 7,261 | The ETF bought 522 new shares of WVE (Wave Life Sciences Ltd). The shares were bought for an average price of 13.91 compared to the previous average buy price of 8.50508. This is 63.5% higher than average price of previous purchases of WVE. |
| TWST - Twist Bioscience Corp | BUY | 190 @ USD 38.04 | USD 7,228 | The ETF bought 190 new shares of TWST (Twist Bioscience Corp). The shares were bought for an average price of 38.04 compared to the previous average buy price of 34.6833. This is 9.7% higher than average price of previous purchases of TWST. |
| TXG - 10X Genomics Inc | BUY | 362 @ USD 19.8 | USD 7,168 | The ETF bought 362 new shares of TXG (10X Genomics Inc). The shares were bought for an average price of 19.8 compared to the previous average buy price of 13.7757. This is 43.7% higher than average price of previous purchases of TXG. |
| TXG - Terex Corporation | BUY | 362 @ USD 19.8 | USD 7,168 | The ETF bought 362 new shares of TXG (Terex Corporation). The shares were bought for an average price of 19.8 compared to the previous average buy price of 13.7757. This is 43.7% higher than average price of previous purchases of TXG. |
| OCUL - Ocular Therapeutix Inc | BUY | 664 @ USD 10.69 | USD 7,098 | The ETF bought 664 new shares of OCUL (Ocular Therapeutix Inc). The shares were bought for an average price of 10.69 compared to the previous average buy price of 11.1087. This is -3.8% lower than average price of previous purchases of OCUL. |
| OLMA - Olema Pharmaceuticals Inc | BUY | 244 @ USD 28.79 | USD 7,025 | The ETF bought 244 new shares of OLMA (Olema Pharmaceuticals Inc). The shares were bought for an average price of 28.79 compared to the previous average buy price of 12.9965. This is 121.5% higher than average price of previous purchases of OLMA. |
| SRPT - Sarepta Therapeutics Inc | BUY | 332 @ USD 21.14 | USD 7,018 | The ETF bought 332 new shares of SRPT (Sarepta Therapeutics Inc). The shares were bought for an average price of 21.14 compared to the previous average buy price of 29.8802. This is -29.3% lower than average price of previous purchases of SRPT. |
| HRMY - Harmony Biosciences Holdings | BUY | 180 @ USD 38.27 | USD 6,889 | The ETF bought 180 new shares of HRMY (Harmony Biosciences Holdings). The shares were bought for an average price of 38.27 compared to the previous average buy price of 33.5753. This is 14.0% higher than average price of previous purchases of HRMY. |
| CNTA - Centessa Pharmaceuticals PLC ADR | BUY | 300 @ USD 22.02 | USD 6,606 | The ETF bought 300 new shares of CNTA (Centessa Pharmaceuticals PLC ADR). The shares were bought for an average price of 22.02 compared to the previous average buy price of 19.6217. This is 12.2% higher than average price of previous purchases of CNTA. |
| AUPH - Aurinia Pharmaceuticals Inc | BUY | 412 @ USD 15.28 | USD 6,295 | The ETF bought 412 new shares of AUPH (Aurinia Pharmaceuticals Inc). The shares were bought for an average price of 15.28 compared to the previous average buy price of 11.4615. This is 33.3% higher than average price of previous purchases of AUPH. |
| LEGN - Legend Biotech Corp | BUY | 262 @ USD 23.7 | USD 6,209 | The ETF bought 262 new shares of LEGN (Legend Biotech Corp). The shares were bought for an average price of 23.7 compared to the previous average buy price of 32.4359. This is -26.9% lower than average price of previous purchases of LEGN. |
| GMAB - Genmab AS | BUY | 182 @ USD 33.95 | USD 6,179 | The ETF bought 182 new shares of GMAB (Genmab AS). The shares were bought for an average price of 33.95 compared to the previous average buy price of 28.2899. This is 20.0% higher than average price of previous purchases of GMAB. |
| ANIP - ANI Pharmaceuticals Inc | BUY | 70 @ USD 84.35 | USD 5,905 | The ETF bought 70 new shares of ANIP (ANI Pharmaceuticals Inc). The shares were bought for an average price of 84.35 compared to the previous average buy price of 74.9661. This is 12.5% higher than average price of previous purchases of ANIP. |
| NRIX - Nurix Therapeutics Inc | BUY | 316 @ USD 18.38 | USD 5,808 | The ETF bought 316 new shares of NRIX (Nurix Therapeutics Inc). The shares were bought for an average price of 18.38 compared to the previous average buy price of 14.7397. This is 24.7% higher than average price of previous purchases of NRIX. |
| VCEL - Vericel Corp Ord | BUY | 158 @ USD 36.59 | USD 5,781 | The ETF bought 158 new shares of VCEL (Vericel Corp Ord). The shares were bought for an average price of 36.59 compared to the previous average buy price of 39.8608. This is -8.2% lower than average price of previous purchases of VCEL. |
| KNSA - Kiniksa Pharmaceuticals Ltd | BUY | 140 @ USD 41.12 | USD 5,757 | The ETF bought 140 new shares of KNSA (Kiniksa Pharmaceuticals Ltd). The shares were bought for an average price of 41.12 compared to the previous average buy price of 33.0939. This is 24.3% higher than average price of previous purchases of KNSA. |
| DVAX - Dynavax Technologies Corporation | BUY | 366 @ USD 15.68 | USD 5,739 | The ETF bought 366 new shares of DVAX (Dynavax Technologies Corporation). The shares were bought for an average price of 15.68 compared to the previous average buy price of 10.8138. This is 45.0% higher than average price of previous purchases of DVAX. |
| SNDX - Syndax Pharmaceuticals Inc | BUY | 270 @ USD 20.72 | USD 5,594 | The ETF bought 270 new shares of SNDX (Syndax Pharmaceuticals Inc). The shares were bought for an average price of 20.72 compared to the previous average buy price of 14.2585. This is 45.3% higher than average price of previous purchases of SNDX. |
| ARDX - Ardelyx Inc | BUY | 758 @ USD 7.36 | USD 5,579 | The ETF bought 758 new shares of ARDX (Ardelyx Inc). The shares were bought for an average price of 7.36 compared to the previous average buy price of 4.97949. This is 47.8% higher than average price of previous purchases of ARDX. |
| HROW - Harrow Health Inc | BUY | 116 @ USD 47.84 | USD 5,549 | The ETF bought 116 new shares of HROW (Harrow Health Inc). The shares were bought for an average price of 47.84 compared to the previous average buy price of 37.437. This is 27.8% higher than average price of previous purchases of HROW. |
| MNKD - MannKind Corp | BUY | 960 @ USD 5.77 | USD 5,539 | The ETF bought 960 new shares of MNKD (MannKind Corp). The shares were bought for an average price of 5.77 compared to the previous average buy price of 4.97456. This is 16.0% higher than average price of previous purchases of MNKD. |
| ERAS - Erasca Inc | BUY | 886 @ USD 6.23 | USD 5,520 | The ETF bought 886 new shares of ERAS (Erasca Inc). The shares were bought for an average price of 6.23 compared to the previous average buy price of 2.12458. This is 193.2% higher than average price of previous purchases of ERAS. |
| ZYME - Zymeworks Inc. Common Stock | BUY | 234 @ USD 23.16 | USD 5,419 | The ETF bought 234 new shares of ZYME (Zymeworks Inc. Common Stock). The shares were bought for an average price of 23.16 compared to the previous average buy price of 17.5944. This is 31.6% higher than average price of previous purchases of ZYME. |
| FTRE - Fortrea Holdings Inc. | BUY | 288 @ USD 18.4 | USD 5,299 | The ETF bought 288 new shares of FTRE (Fortrea Holdings Inc.). The shares were bought for an average price of 18.4 compared to the previous average buy price of 8.69582. This is 111.6% higher than average price of previous purchases of FTRE. |
| STOK - Stoke Therapeutics Inc | BUY | 178 @ USD 29.42 | USD 5,237 | The ETF bought 178 new shares of STOK (Stoke Therapeutics Inc). The shares were bought for an average price of 29.42 compared to the previous average buy price of 20.0592. This is 46.7% higher than average price of previous purchases of STOK. |
| PHVS - Pharvaris BV | BUY | 200 @ USD 26.1 | USD 5,220 | The ETF bought 200 new shares of PHVS (Pharvaris BV). The shares were bought for an average price of 26.1 compared to the previous average buy price of 25.7847. This is 1.2% higher than average price of previous purchases of PHVS. |
| AGIO - Agios Pharm | BUY | 182 @ USD 28.32 | USD 5,154 | The ETF bought 182 new shares of AGIO (Agios Pharm). The shares were bought for an average price of 28.32 compared to the previous average buy price of 33.7729. This is -16.1% lower than average price of previous purchases of AGIO. |
| NVCR - Novocure Ltd | BUY | 350 @ USD 14.18 | USD 4,963 | The ETF bought 350 new shares of NVCR (Novocure Ltd). The shares were bought for an average price of 14.18 compared to the previous average buy price of 15.3514. This is -7.6% lower than average price of previous purchases of NVCR. |
| COLL - Collegium Pharmaceutical Inc | BUY | 98 @ USD 48.15 | USD 4,719 | The ETF bought 98 new shares of COLL (Collegium Pharmaceutical Inc). The shares were bought for an average price of 48.15 compared to the previous average buy price of 35.9633. This is 33.9% higher than average price of previous purchases of COLL. |
| BCRX - BioCryst Pharmaceuticals Inc | BUY | 658 @ USD 7.09 | USD 4,665 | The ETF bought 658 new shares of BCRX (BioCryst Pharmaceuticals Inc). The shares were bought for an average price of 7.09 compared to the previous average buy price of 8.02009. This is -11.6% lower than average price of previous purchases of BCRX. |
| PGEN - Precigen Inc | BUY | 1,106 @ USD 4.135 | USD 4,573 | The ETF bought 1106 new shares of PGEN (Precigen Inc). The shares were bought for an average price of 4.135 compared to the previous average buy price of 3.01373. This is 37.2% higher than average price of previous purchases of PGEN. |
| ELVN - Enliven Therapeutics Inc. | BUY | 182 @ USD 25.03 | USD 4,555 | The ETF bought 182 new shares of ELVN (Enliven Therapeutics Inc.). The shares were bought for an average price of 25.03 compared to the previous average buy price of 20.5406. This is 21.9% higher than average price of previous purchases of ELVN. |
| INVA - Innoviva Inc | BUY | 234 @ USD 19.44 | USD 4,549 | The ETF bought 234 new shares of INVA (Innoviva Inc). The shares were bought for an average price of 19.44 compared to the previous average buy price of 19.6546. This is -1.1% lower than average price of previous purchases of INVA. |
| TNGX - Tango Therapeutics Inc | BUY | 420 @ USD 10.66 | USD 4,477 | The ETF bought 420 new shares of TNGX (Tango Therapeutics Inc). The shares were bought for an average price of 10.66 compared to the previous average buy price of 7.68989. This is 38.6% higher than average price of previous purchases of TNGX. |
| QURE - Uniqure NV | BUY | 194 @ USD 23.04 | USD 4,470 | The ETF bought 194 new shares of QURE (Uniqure NV). The shares were bought for an average price of 23.04 compared to the previous average buy price of 23.5166. This is -2.0% lower than average price of previous purchases of QURE. |
| IMCR - Immunocore Holdings Ltd | BUY | 136 @ USD 32.64 | USD 4,439 | The ETF bought 136 new shares of IMCR (Immunocore Holdings Ltd). The shares were bought for an average price of 32.64 compared to the previous average buy price of 34.2824. This is -4.8% lower than average price of previous purchases of IMCR. |
| MNMD - Mind Medicine Inc | BUY | 308 @ USD 13.88 | USD 4,275 | The ETF bought 308 new shares of MNMD (Mind Medicine Inc). The shares were bought for an average price of 13.88 compared to the previous average buy price of 10.5358. This is 31.7% higher than average price of previous purchases of MNMD. |
| AMLX - Amylyx Pharmaceuticals Inc | BUY | 344 @ USD 12.39 | USD 4,262 | The ETF bought 344 new shares of AMLX (Amylyx Pharmaceuticals Inc). The shares were bought for an average price of 12.39 compared to the previous average buy price of 9.20388. This is 34.6% higher than average price of previous purchases of AMLX. |
| AMPH - Amphastar P | BUY | 144 @ USD 29.4 | USD 4,234 | The ETF bought 144 new shares of AMPH (Amphastar P). The shares were bought for an average price of 29.4 compared to the previous average buy price of 25.8742. This is 13.6% higher than average price of previous purchases of AMPH. |
| RLAY - Relay Therapeutics Inc | BUY | 542 @ USD 7.8 | USD 4,228 | The ETF bought 542 new shares of RLAY (Relay Therapeutics Inc). The shares were bought for an average price of 7.8 compared to the previous average buy price of 4.98775. This is 56.4% higher than average price of previous purchases of RLAY. |
| ANAB - AnaptysBio Inc | BUY | 86 @ USD 49.03 | USD 4,217 | The ETF bought 86 new shares of ANAB (AnaptysBio Inc). The shares were bought for an average price of 49.03 compared to the previous average buy price of 29.0246. This is 68.9% higher than average price of previous purchases of ANAB. |
| ABCL - Abcellera Biologics Inc | BUY | 930 @ USD 4.52 | USD 4,204 | The ETF bought 930 new shares of ABCL (Abcellera Biologics Inc). The shares were bought for an average price of 4.52 compared to the previous average buy price of 3.84492. This is 17.6% higher than average price of previous purchases of ABCL. |
| TSHA - Taysha Gene Therapies Inc | BUY | 858 @ USD 4.86 | USD 4,170 | The ETF bought 858 new shares of TSHA (Taysha Gene Therapies Inc). The shares were bought for an average price of 4.86 compared to the previous average buy price of 3.31634. This is 46.5% higher than average price of previous purchases of TSHA. |
| NTLA - Intellia Therapeutics Inc | BUY | 360 @ USD 11.43 | USD 4,115 | The ETF bought 360 new shares of NTLA (Intellia Therapeutics Inc). The shares were bought for an average price of 11.43 compared to the previous average buy price of 11.4481. This is -0.2% lower than average price of previous purchases of NTLA. |
| XERS - Xeris Pharmaceuticals Inc | BUY | 518 @ USD 7.87 | USD 4,077 | The ETF bought 518 new shares of XERS (Xeris Pharmaceuticals Inc). The shares were bought for an average price of 7.87 compared to the previous average buy price of 6.26088. This is 25.7% higher than average price of previous purchases of XERS. |
| NVAX - Novavax Inc | BUY | 508 @ USD 7.75 | USD 3,937 | The ETF bought 508 new shares of NVAX (Novavax Inc). The shares were bought for an average price of 7.75 compared to the previous average buy price of 7.20435. This is 7.6% higher than average price of previous purchases of NVAX. |
| NVAX - Hana Microelectronics Public Company Limited | BUY | 508 @ USD 7.75 | USD 3,937 | The ETF bought 508 new shares of NVAX (Hana Microelectronics Public Company Limited). The shares were bought for an average price of 7.75 compared to the previous average buy price of 7.20435. This is 7.6% higher than average price of previous purchases of NVAX. |
| SANA - Sana Biotechnology Inc | BUY | 830 @ USD 4.58 | USD 3,801 | The ETF bought 830 new shares of SANA (Sana Biotechnology Inc). The shares were bought for an average price of 4.58 compared to the previous average buy price of 3.51873. This is 30.2% higher than average price of previous purchases of SANA. |
| SVRA - Savara Inc | BUY | 638 @ USD 5.77 | USD 3,681 | The ETF bought 638 new shares of SVRA (Savara Inc). The shares were bought for an average price of 5.77 compared to the previous average buy price of 4.26315. This is 35.3% higher than average price of previous purchases of SVRA. |
| CSTL - Castle Biosciences Inc | BUY | 90 @ USD 39.66 | USD 3,569 | The ETF bought 90 new shares of CSTL (Castle Biosciences Inc). The shares were bought for an average price of 39.66 compared to the previous average buy price of 26.6751. This is 48.7% higher than average price of previous purchases of CSTL. |
| SPRY - Silverback Therapeutics Inc | BUY | 308 @ USD 11.38 | USD 3,505 | The ETF bought 308 new shares of SPRY (Silverback Therapeutics Inc). The shares were bought for an average price of 11.38 compared to the previous average buy price of 12.4102. This is -8.3% lower than average price of previous purchases of SPRY. |
| GRFS - Grifols SA ADR | BUY | 382 @ USD 9.14 | USD 3,491 | The ETF bought 382 new shares of GRFS (Grifols SA ADR). The shares were bought for an average price of 9.14 compared to the previous average buy price of 9.21885. This is -0.9% lower than average price of previous purchases of GRFS. |
| PHAT - Phathom Pharmaceuticals Inc | BUY | 222 @ USD 14.47 | USD 3,212 | The ETF bought 222 new shares of PHAT (Phathom Pharmaceuticals Inc). The shares were bought for an average price of 14.47 compared to the previous average buy price of 10.7131. This is 35.1% higher than average price of previous purchases of PHAT. |
| XNCR - Xencor Inc | BUY | 224 @ USD 14.17 | USD 3,174 | The ETF bought 224 new shares of XNCR (Xencor Inc). The shares were bought for an average price of 14.17 compared to the previous average buy price of 12.5807. This is 12.6% higher than average price of previous purchases of XNCR. |
| URGN - UroGen Pharma Ltd | BUY | 146 @ USD 21.45 | USD 3,132 | The ETF bought 146 new shares of URGN (UroGen Pharma Ltd). The shares were bought for an average price of 21.45 compared to the previous average buy price of 17.1522. This is 25.1% higher than average price of previous purchases of URGN. |
| VTYX - Ventyx Biosciences Inc | BUY | 224 @ USD 13.84 | USD 3,100 | The ETF bought 224 new shares of VTYX (Ventyx Biosciences Inc). The shares were bought for an average price of 13.84 compared to the previous average buy price of 12.3229. This is 12.3% higher than average price of previous purchases of VTYX. |
| PCRX - Pacira BioSciences, Inc. | BUY | 134 @ USD 22.93 | USD 3,073 | The ETF bought 134 new shares of PCRX (Pacira BioSciences, Inc.). The shares were bought for an average price of 22.93 compared to the previous average buy price of 23.8871. This is -4.0% lower than average price of previous purchases of PCRX. |
| TBPH - Theravance Biopharma Inc | BUY | 156 @ USD 19.65 | USD 3,065 | The ETF bought 156 new shares of TBPH (Theravance Biopharma Inc). The shares were bought for an average price of 19.65 compared to the previous average buy price of 13.7044. This is 43.4% higher than average price of previous purchases of TBPH. |
| RAPT - RAPT Therapeutics Inc | BUY | 86 @ USD 34.4 | USD 2,958 | The ETF bought 86 new shares of RAPT (RAPT Therapeutics Inc). The shares were bought for an average price of 34.4 compared to the previous average buy price of 32.99. This is 4.3% higher than average price of previous purchases of RAPT. |
| IOVA - Iovance Biotherapeutics Inc | BUY | 1,182 @ USD 2.4 | USD 2,837 | The ETF bought 1182 new shares of IOVA (Iovance Biotherapeutics Inc). The shares were bought for an average price of 2.4 compared to the previous average buy price of 2.39997. This is 0.0% higher than average price of previous purchases of IOVA. |
| GERN - Geron Corporation | BUY | 1,962 @ USD 1.43 | USD 2,806 | The ETF bought 1962 new shares of GERN (Geron Corporation). The shares were bought for an average price of 1.43 compared to the previous average buy price of 1.43499. This is -0.3% lower than average price of previous purchases of GERN. |
| ORIC - Oric Pharmaceuticals Inc | BUY | 298 @ USD 9.15001 | USD 2,727 | The ETF bought 298 new shares of ORIC (Oric Pharmaceuticals Inc). The shares were bought for an average price of 9.15001 compared to the previous average buy price of 10.6022. This is -13.7% lower than average price of previous purchases of ORIC. |
| ABUS - Arbutus Biopharma Corp | BUY | 604 @ USD 4.5 | USD 2,718 | The ETF bought 604 new shares of ABUS (Arbutus Biopharma Corp). The shares were bought for an average price of 4.5 compared to the previous average buy price of 3.86635. This is 16.4% higher than average price of previous purchases of ABUS. |
| PAHC - Phibro Animal Health Corporation | BUY | 66 @ USD 39.83 | USD 2,629 | The ETF bought 66 new shares of PAHC (Phibro Animal Health Corporation). The shares were bought for an average price of 39.83 compared to the previous average buy price of 31.7052. This is 25.6% higher than average price of previous purchases of PAHC. |
| KALV - Kalvista Pharmaceuticals Inc | BUY | 158 @ USD 16.39 | USD 2,590 | The ETF bought 158 new shares of KALV (Kalvista Pharmaceuticals Inc). The shares were bought for an average price of 16.39 compared to the previous average buy price of 13.6399. This is 20.2% higher than average price of previous purchases of KALV. |
| JANX - Janux Therapeutics Inc | BUY | 184 @ USD 14.03 | USD 2,582 | The ETF bought 184 new shares of JANX (Janux Therapeutics Inc). The shares were bought for an average price of 14.03 compared to the previous average buy price of 25.9448. This is -45.9% lower than average price of previous purchases of JANX. |
| VIR - Vir Biotechnology Inc | BUY | 426 @ USD 5.92001 | USD 2,522 | The ETF bought 426 new shares of VIR (Vir Biotechnology Inc). The shares were bought for an average price of 5.92001 compared to the previous average buy price of 5.92943. This is -0.2% lower than average price of previous purchases of VIR. |
| VIR - Vidrala S.A | BUY | 426 @ USD 5.92001 | USD 2,522 | The ETF bought 426 new shares of VIR (Vidrala S.A). The shares were bought for an average price of 5.92001 compared to the previous average buy price of 5.92943. This is -0.2% lower than average price of previous purchases of VIR. |
| PRME - Prime Medicine, Inc. Common Stock | BUY | 584 @ USD 4.28 | USD 2,500 | The ETF bought 584 new shares of PRME (Prime Medicine, Inc. Common Stock). The shares were bought for an average price of 4.28 compared to the previous average buy price of 4.33377. This is -1.2% lower than average price of previous purchases of PRME. |
| KURA - Kura Oncology Inc | BUY | 272 @ USD 9.16999 | USD 2,494 | The ETF bought 272 new shares of KURA (Kura Oncology Inc). The shares were bought for an average price of 9.16999 compared to the previous average buy price of 8.32415. This is 10.2% higher than average price of previous purchases of KURA. |
| ARVN - Arvinas Inc | BUY | 202 @ USD 12.15 | USD 2,454 | The ETF bought 202 new shares of ARVN (Arvinas Inc). The shares were bought for an average price of 12.15 compared to the previous average buy price of 9.98991. This is 21.6% higher than average price of previous purchases of ARVN. |
| RGNX - Regenxbio Inc | BUY | 158 @ USD 15.08 | USD 2,383 | The ETF bought 158 new shares of RGNX (Regenxbio Inc). The shares were bought for an average price of 15.08 compared to the previous average buy price of 10.1642. This is 48.4% higher than average price of previous purchases of RGNX. |
| IRWD - Ironwood Pharmaceuticals Inc | BUY | 512 @ USD 4.47 | USD 2,289 | The ETF bought 512 new shares of IRWD (Ironwood Pharmaceuticals Inc). The shares were bought for an average price of 4.47 compared to the previous average buy price of 2.39569. This is 86.6% higher than average price of previous purchases of IRWD. |
| ZLAB - Zai Lab Ltd | BUY | 122 @ USD 18.39 | USD 2,244 | The ETF bought 122 new shares of ZLAB (Zai Lab Ltd). The shares were bought for an average price of 18.39 compared to the previous average buy price of 30.8537. This is -40.4% lower than average price of previous purchases of ZLAB. |
| REPL - Replimune Group Inc | BUY | 246 @ USD 8.10501 | USD 1,994 | The ETF bought 246 new shares of REPL (Replimune Group Inc). The shares were bought for an average price of 8.10501 compared to the previous average buy price of 9.13915. This is -11.3% lower than average price of previous purchases of REPL. |
| CGEM - Cullinan Oncology LLC | BUY | 182 @ USD 10.61 | USD 1,931 | The ETF bought 182 new shares of CGEM (Cullinan Oncology LLC). The shares were bought for an average price of 10.61 compared to the previous average buy price of 8.63668. This is 22.8% higher than average price of previous purchases of CGEM. |
| PACB - Pacific Biosciences of California | BUY | 954 @ USD 2.01 | USD 1,918 | The ETF bought 954 new shares of PACB (Pacific Biosciences of California). The shares were bought for an average price of 2.01 compared to the previous average buy price of 1.70372. This is 18.0% higher than average price of previous purchases of PACB. |
| KROS - Keros Therapeutics Inc | BUY | 96 @ USD 18.88 | USD 1,812 | The ETF bought 96 new shares of KROS (Keros Therapeutics Inc). The shares were bought for an average price of 18.88 compared to the previous average buy price of 15.907. This is 18.7% higher than average price of previous purchases of KROS. |
| MRVI - Maravai Lifesciences Holdings Inc | BUY | 458 @ USD 3.94 | USD 1,805 | The ETF bought 458 new shares of MRVI (Maravai Lifesciences Holdings Inc). The shares were bought for an average price of 3.94 compared to the previous average buy price of 2.96162. This is 33.0% higher than average price of previous purchases of MRVI. |
| MGTX - MeiraGTx Holdings PLC | BUY | 244 @ USD 7.24 | USD 1,767 | The ETF bought 244 new shares of MGTX (MeiraGTx Holdings PLC). The shares were bought for an average price of 7.24 compared to the previous average buy price of 7.44487. This is -2.8% lower than average price of previous purchases of MGTX. |
| PRTA - Prothena Corporation plc | BUY | 184 @ USD 8.91 | USD 1,639 | The ETF bought 184 new shares of PRTA (Prothena Corporation plc). The shares were bought for an average price of 8.91 compared to the previous average buy price of 9.44663. This is -5.7% lower than average price of previous purchases of PRTA. |
| FULC - Fulcrum Therapeutics Inc | BUY | 170 @ USD 9.51 | USD 1,617 | The ETF bought 170 new shares of FULC (Fulcrum Therapeutics Inc). The shares were bought for an average price of 9.51 compared to the previous average buy price of 10.2529. This is -7.2% lower than average price of previous purchases of FULC. |
| SIGA - SIGA Technologies Inc | BUY | 236 @ USD 6.58999 | USD 1,555 | The ETF bought 236 new shares of SIGA (SIGA Technologies Inc). The shares were bought for an average price of 6.58999 compared to the previous average buy price of 6.6311. This is -0.6% lower than average price of previous purchases of SIGA. |
| LYEL - Lyell Immunopharma Inc | BUY | 64 @ USD 23.77 | USD 1,521 | The ETF bought 64 new shares of LYEL (Lyell Immunopharma Inc). The shares were bought for an average price of 23.77 compared to the previous average buy price of 8.74829. This is 171.7% higher than average price of previous purchases of LYEL. |
| GLPG - Galapagos NV ADR | BUY | 44 @ USD 33.11 | USD 1,457 | The ETF bought 44 new shares of GLPG (Galapagos NV ADR). The shares were bought for an average price of 33.11 compared to the previous average buy price of 29.8309. This is 11.0% higher than average price of previous purchases of GLPG. |
| GLPG - Galapagos N.V. | BUY | 44 @ USD 33.11 | USD 1,457 | The ETF bought 44 new shares of GLPG (Galapagos N.V.). The shares were bought for an average price of 33.11 compared to the previous average buy price of 29.8309. This is 11.0% higher than average price of previous purchases of GLPG. |
| VNDA - Vanda Pharmaceuticals Inc | BUY | 186 @ USD 7.41 | USD 1,378 | The ETF bought 186 new shares of VNDA (Vanda Pharmaceuticals Inc). The shares were bought for an average price of 7.41 compared to the previous average buy price of 5.0081. This is 48.0% higher than average price of previous purchases of VNDA. |
| ALT - Altitude Group Plc | BUY | 332 @ USD 4.05001 | USD 1,345 | The ETF bought 332 new shares of ALT (Altitude Group Plc). The shares were bought for an average price of 4.05001 compared to the previous average buy price of 4.85149. This is -16.5% lower than average price of previous purchases of ALT. |
| RCKT - Rocket Pharmaceuticals Inc | BUY | 360 @ USD 3.60001 | USD 1,296 | The ETF bought 360 new shares of RCKT (Rocket Pharmaceuticals Inc). The shares were bought for an average price of 3.60001 compared to the previous average buy price of 4.62033. This is -22.1% lower than average price of previous purchases of RCKT. |
| FDMT - 4D Molecular Therapeutics Inc | BUY | 168 @ USD 7.5 | USD 1,260 | The ETF bought 168 new shares of FDMT (4D Molecular Therapeutics Inc). The shares were bought for an average price of 7.5 compared to the previous average buy price of 7.75429. This is -3.3% lower than average price of previous purchases of FDMT. |
| AVXL - Anavex Life Sciences Corp | BUY | 290 @ USD 4.29 | USD 1,244 | The ETF bought 290 new shares of AVXL (Anavex Life Sciences Corp). The shares were bought for an average price of 4.29 compared to the previous average buy price of 7.95322. This is -46.1% lower than average price of previous purchases of AVXL. |
| ALLO - Allogene Therapeutics Inc | BUY | 742 @ USD 1.67 | USD 1,239 | The ETF bought 742 new shares of ALLO (Allogene Therapeutics Inc). The shares were bought for an average price of 1.67 compared to the previous average buy price of 1.35288. This is 23.4% higher than average price of previous purchases of ALLO. |
| TRDA - Entrada Therapeutics Inc | BUY | 120 @ USD 9.95001 | USD 1,194 | The ETF bought 120 new shares of TRDA (Entrada Therapeutics Inc). The shares were bought for an average price of 9.95001 compared to the previous average buy price of 8.2875. This is 20.1% higher than average price of previous purchases of TRDA. |
| ACIU - AC Immune Ltd | BUY | 338 @ USD 3.52001 | USD 1,190 | The ETF bought 338 new shares of ACIU (AC Immune Ltd). The shares were bought for an average price of 3.52001 compared to the previous average buy price of 2.60069. This is 35.3% higher than average price of previous purchases of ACIU. |
| EOLS - Evolus Inc | BUY | 206 @ USD 5.77 | USD 1,189 | The ETF bought 206 new shares of EOLS (Evolus Inc). The shares were bought for an average price of 5.77 compared to the previous average buy price of 8.4995. This is -32.1% lower than average price of previous purchases of EOLS. |
| BCYC - Bicycle Therapeutics Ltd | BUY | 160 @ USD 6.58 | USD 1,053 | The ETF bought 160 new shares of BCYC (Bicycle Therapeutics Ltd). The shares were bought for an average price of 6.58 compared to the previous average buy price of 8.11405. This is -18.9% lower than average price of previous purchases of BCYC. |
| AVIR - Atea Pharmaceuticals Inc | BUY | 286 @ USD 3.60999 | USD 1,032 | The ETF bought 286 new shares of AVIR (Atea Pharmaceuticals Inc). The shares were bought for an average price of 3.60999 compared to the previous average buy price of 3.25992. This is 10.7% higher than average price of previous purchases of AVIR. |
| ACRS - Aclaris Therapeutics Inc | BUY | 348 @ USD 2.66 | USD 926 | The ETF bought 348 new shares of ACRS (Aclaris Therapeutics Inc). The shares were bought for an average price of 2.66 compared to the previous average buy price of 2.72258. This is -2.3% lower than average price of previous purchases of ACRS. |
| AUTL - Autolus Therapeutics Ltd | BUY | 604 @ USD 1.5 | USD 906 | The ETF bought 604 new shares of AUTL (Autolus Therapeutics Ltd). The shares were bought for an average price of 1.5 compared to the previous average buy price of 1.7455. This is -14.1% lower than average price of previous purchases of AUTL. |
| OABI - OmniAb Inc. | BUY | 424 @ USD 1.91 | USD 810 | The ETF bought 424 new shares of OABI (OmniAb Inc.). The shares were bought for an average price of 1.91 compared to the previous average buy price of 1.88851. This is 1.1% higher than average price of previous purchases of OABI. |
| ARCT - Arcturus Therapeutics Holdings Inc | BUY | 98 @ USD 7.53 | USD 738 | The ETF bought 98 new shares of ARCT (Arcturus Therapeutics Holdings Inc). The shares were bought for an average price of 7.53 compared to the previous average buy price of 12.2729. This is -38.6% lower than average price of previous purchases of ARCT. |
| EDIT - Editas Medicine Inc | BUY | 332 @ USD 2.13 | USD 707 | The ETF bought 332 new shares of EDIT (Editas Medicine Inc). The shares were bought for an average price of 2.13 compared to the previous average buy price of 2.59439. This is -17.9% lower than average price of previous purchases of EDIT. |
| VYGR - Voyager Therapeutics Inc | BUY | 178 @ USD 3.9 | USD 694 | The ETF bought 178 new shares of VYGR (Voyager Therapeutics Inc). The shares were bought for an average price of 3.9 compared to the previous average buy price of 3.93712. This is -0.9% lower than average price of previous purchases of VYGR. |
| CABA - Cabaletta Bio Inc | BUY | 312 @ USD 2.20999 | USD 690 | The ETF bought 312 new shares of CABA (Cabaletta Bio Inc). The shares were bought for an average price of 2.20999 compared to the previous average buy price of 2.13437. This is 3.5% higher than average price of previous purchases of CABA. |
| HUMA - Humacyte Inc | BUY | 564 @ USD 1.13 | USD 637 | The ETF bought 564 new shares of HUMA (Humacyte Inc). The shares were bought for an average price of 1.13 compared to the previous average buy price of 1.96427. This is -42.5% lower than average price of previous purchases of HUMA. |
| CRBU - Caribou Biosciences Inc | BUY | 304 @ USD 1.58 | USD 480 | The ETF bought 304 new shares of CRBU (Caribou Biosciences Inc). The shares were bought for an average price of 1.58 compared to the previous average buy price of 1.69843. This is -7.0% lower than average price of previous purchases of CRBU. |
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| BEAM - Beam Therapeutics Inc | HOLD | 0 @ USD 33.69 | USD 0 | The current share valuation price of BEAM based on adjusted close was USD 33.69. The average price that BEAM shares were previous bought at was USD 22.1134. The current market price is 52.4% higher than average price they were purchased at. The value of the holding in BEAM has increased by USD 421,382 compared to the previous valuation of Beam Therapeutics Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| DAWN - Day One Biopharmaceuticals Inc | HOLD | 0 @ USD 11.33 | USD 0 | The current share valuation price of DAWN based on adjusted close was USD 11.33. The average price that DAWN shares were previous bought at was USD 7.76268. The current market price is 46.0% higher than average price they were purchased at. The value of the holding in DAWN has increased by USD 162,166 compared to the previous valuation of Day One Biopharmaceuticals Inc however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.06885. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2026-01-12 this would crystalise an overall loss. |